DNA Script is a leading company in manufacturing de novo synthetic nucleic acids using an enzymatic technology. The company aims at accelerating innovation in life science and technology through the decentralization of rapid, on demand and high-quality DNA synthesis. DNA Script's approach leverages nature's billions of years of evolution in synthesizing DNA to set a new standard for customizing nucleic acid synthesis thus accelerating discovery in genetics, genomics, and synthetic biology. Discovery disciplines with profound impacts upon humanity such as biopharma, translational genetics and even molecular information storage all start with synthetic DNA.
To date, DNA Script has raised over $100M of financing, mostly through leading investors such as LSP, BPI France, Illumina Ventures, Merck Ventures, Sofinnova Partners, Kurma Partners and Idinvest.
DNA Script has its research facility headquartered in Paris, France, and is in the process of establishing its commercial and development teams near San Francisco.